(abatacept) is indicated for adult patients with moderately to severely active RA to: reduce signs and symptoms, induce major clinical response, inhibit the progression of structural damage, and improve physical function. ORENCIA may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists.
Important Limitations of Use:
ORENCIA should not be administered concomitantly with TNF antagonists and is not recommended for use concomitantly with other biologic RA therapy, such as anakinra.
ORENCIA is available as a lyophilized powder for intravenous (IV) infusion and as a solution for subcutaneous (SC) injection.
ORENCIA is available as a subcutaneous formulation for appropriate adult patients
Subcutaneous ORENCIA demonstrated similar efficacy (non-inferior for American College of Rheumatology [ACR] 20 responses at 6 months) to the intravenous formulation and a consistent safety profile at 6 months.2
View the ACQUIRE Study Results
In 2010, 44% of patients who started on ORENCIA IV were prescribed it as their first biologica,*
aSDI provides an anonymous patient-level database derived from healthcare claims; however, there are some limitations to these data: sampling consists of ~25% of medical claims submitted by physician offices and medical clinics to payers, used to project the entire population of prescribers within medical offices and clinics in the United States.
*Based on annual SDI claims data from Q1-Q4 2010 (projected from a sample size of 663).3